Cardiovascular Medicine
Initial nondrug therapy of acute SVT
Vagal maneuvers
Most common cause of infective endocarditis in persons who inject drugs
Staphylococcus aureus
Initial test for PH
Transthoracic echocardiography
Initial treatment of giant cell arteritis when suspected
High-dose glucocorticoids
Initial treatment of warm autoimmune hemolytic anemia
Glucocorticoids
Diagnostic test for CAD when LBBB is present
Vasodilator stress myocardial perfusion imaging
Preferred treatment for methicillin-susceptible Staphylococcus aureus bacteremia
Cefazolin or an antistaphylococcal penicillin
Initial imaging for CTEPH
V/Q scan
Autoantibody most specific for systemic sclerosis
Anti-centromere or anti-topoisomerase I (Scl-70), depending on subtype
Most common acquired thrombophilia
Antiphospholipid syndrome
Cardiac biomarker to distinguish restrictive cardiomyopathy (elevated) from constrictive pericarditis (normal)
BNP
Most sensitive test for Clostridioides difficile infection
Nucleic acid amplification test (NAAT) with appropriate testing strategy
Treatment for CTEPH
Pulmonary thromboendarterectomy and anticoagulation
First-line treatment for ANCA-associated vasculitis with severe disease
Glucocorticoids plus rituximab or cyclophosphamide
Treatment for thrombotic thrombocytopenic purpura
Plasma exchange plus glucocorticoids
Disease-specific therapy for transthyretin amyloid cardiac amyloidosis
Tafamidis, acoramidis, vutrisiran
Preferred treatment for cryptococcal meningitis in patients with HIV
Liposomal amphotericin B plus flucytosine
Systemic sclerosis variant associated with PAH
Limited cutaneous systemic sclerosis
Antibody associated with antisynthetase syndrome
Anti–Jo-1 antibody
Mutation associated with hereditary hemochromatosis
HFE C282Y
Imaging to distinguish different subtypes of cardiac amyloid
99m-Technetium pyrophosphate scintigraphy
Recommended timing of ART after cryptococcal meningitis
Delay ART for approximately 4-6 weeks after antifungal therapy is started
First-line therapy for PAH if tolerated
Endothelin-1 receptor antagonist plus PDE-5 inhibitor
Treatment for diffuse systemic sclerosis–associated interstitial lung disease
Mycophenolate mofetil
Initial treatment for acute promyelocytic leukemia
All-trans retinoic acid (ATRA) plus arsenic trioxide